Following announcement of prioritized development strategy for evorpacept in combination with anti-cancer antibodies at R&D Day in March, Company is on track to initiate Phase 2 ASPEN-Breast and Phase ...

Appian (Nasdaq: APPN) today announced financial results for the first quarter ended March 31, 2025. "In Q1, Appian continued to demonstrate our earnings ...